Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 16/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088193 | 0.91 | SCNN1A (0.46) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL14190124 | 0.90 | SCNN1A (0.43) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL4881560 | 0.90 | SCNN1A (0.46) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL17919120 | 0.89 | SCNN1A (0.42) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL14088232 | 0.88 | SCNN1A (0.44) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL4885446 | 0.87 | SCNN1A (0.43) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL14088228 | 0.84 | SCNN1A (0.48) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL17919117 | 0.84 | SCNN1A (0.40) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL14088245 | 0.84 | SCNN1A (0.46) | SCNN1AALDH1A1GLAHSD17B10KDM4E | |
| SCHEMBL14217617 | 0.84 | SCNN1A (0.44) | SCNN1AALDH1A1GLAHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7375107-B2 | Such as N-(6-aminohexyl)-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine Dihydrochloride; for hydration of mucosal surfaces, treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, esophogitis, emphysema, and pneumonia | PARION SCIENCES, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375107-B2 | Such as N-(6-aminohexyl)-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine Dihydrochloride; for hydration of mucosal surfaces, treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, esophogitis, emphysema, and pneumonia | PARION SCIENCES, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375107-B2 | Such as N-(6-aminohexyl)-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine Dihydrochloride; for hydration of mucosal surfaces, treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, esophogitis, emphysema, and pneumonia | PARION SCIENCES, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050080092-A1 | Alaphatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080092-A1 | Alaphatic pyrazinoylguanidine sodium channel blockers | KCNH1, CACNA1B, CACNA1C | SCNN1A 66/4885ALDH1A1 1639/4885GLA 1957/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885ALDH1A1 1362/4885GLA 948/4885 |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH1, CACNA1B, CACNA1C | SCNN1A 66/4885ALDH1A1 1639/4885GLA 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.